Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

The role of CRF receptors in anxiety and depression: Implications of the novel CRF1 agonist cortagine

MPG-Autoren
/persons/resource/persons182453

Todorovic,  Cedomir
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182214

Jahn,  Olaf
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182447

Tezval,  Hossein
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182200

Hippel,  Cathrin
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

/persons/resource/persons182423

Spiess,  Joachim
Molecular neuroendocrinology, Max Planck Institute of Experimental Medicine, Max Planck Society;

Externe Ressourcen
Es sind keine externen Ressourcen hinterlegt
Volltexte (beschränkter Zugriff)
Für Ihren IP-Bereich sind aktuell keine Volltexte freigegeben.
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte in PuRe verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Todorovic, C., Jahn, O., Tezval, H., Hippel, C., & Spiess, J. (2005). The role of CRF receptors in anxiety and depression: Implications of the novel CRF1 agonist cortagine. Neuroscience & Biobehavioral Reviews, 29(8), 1323-1333. doi:10.1016/j.neubiorev.2005.04.014.


Zitierlink: https://hdl.handle.net/21.11116/0000-000A-E92F-C
Zusammenfassung
Corticotropin-releasing factor (CRF), a 41 amino acid peptide exhibits its actions through two pharmacologically distinct CRF receptor
subtypes CRF1 and CRF2. Regulation of the relative contribution of the two CRF receptors to central CRF activity may be essential in
coordinating physiological responses to stress. To facilitate the analysis of their differential involvement, we recently developed a CRF1-
selective agonist cortagine by synthesis of chimeric peptides derived from human/rat CRF, ovine CRF, and sauvagine. Cortagine was
analyzed in behavioral experiments using male wild type and CRF2-deficient C57BL/6J mice for its action on anxiety- and depression-like
behaviors. In contrast to the current hypothesis that increased CRF1 activity facilitates the expression of anxiety- and depression-like
behavior, cortagine combines anxiogenic properties with antidepressant effects. In this article, we show that antidepressant effects are
partially mediated by CRF1 of the dorsal hippocampus. Possible pathways responsible for the paradoxical antidepressant effects observed
after CRF1 activation are discussed.